CDTX Cidara Therapeutics Inc.

1.61
0  0%
Previous Close 1.61
Open 1.61
Price To Book 0.98
Market Cap 42,893,380
Shares 26,641,851
Volume 2,186
Short Ratio
Av. Daily Volume 143,085

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due mid-2020.
Rezafungin (CD101) ReSTORE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 3 trial pending funding.
Rezafungin (CD101) ReSPECT
Prophylaxis
Phase 2 STRIVE B readout due mid-2019.
Rezafungin (CD101) STRIVE B
Candidemia

Latest News

  1. X-Biotix Therapeutics Joins Antimicrobials Working Group
  2. Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
  3. Imagine Owning Cidara Therapeutics (NASDAQ:CDTX) And Trying To Stomach The 85% Share Price Drop
  4. Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
  5. Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019
  6. What Makes Cidara Therapeutics (CDTX) a New Buy Stock
  7. Cidara Therapeutics: 1Q Earnings Snapshot
  8. Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
  9. Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019
  10. Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program
  11. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  12. Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
  13. Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  14. Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting
  15. Have Insiders Been Buying Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares?
  16. Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
  17. Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
  18. Antimicrobials Working Group Announces Updates to Leadership Team
  19. How Does Investing In Cidara Therapeutics, Inc. (NASDAQ:CDTX) Impact The Volatility Of Your Portfolio?
  20. Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary